Compound Selection. Each LNA Compound delivered by Santaris to Enzon will be identified by Santaris pursuant to the selection process set forth in Schedule 5.4A (the “Compound Selection Process”) and shall satisfy the acceptance criteria set forth for such Additional Target in Schedule 5.4B (the “Compound Acceptance Criteria”). Following the Compound Selection Process, Santaris shall provide Enzon with written reports detailing the results of such process, including its design, synthesis, first screening efforts, second screening efforts, as well as the sequences of any and all LNA Compounds resulting from such process that meet the Compound Acceptance Criteria. Upon Santaris’ delivery, at Santaris’ cost, of [**Redacted**] of each of [**Redacted**] LNA Compounds that meet the Compound Acceptance Criteria each of which is an “Accepted LNA Compound” for Enzon’s [**Redacted**] (which LNA Compounds shall satisfy the obligations of Santaris under Section 5.3), Enzon shall pay the required amount under Section 7.3; provided, however, in the event that Santaris elects to deliver the LNA Compounds to Enzon more frequently than with respect to [**Redacted**] Additional Target every [**Redacted**] pursuant to Section 5.3, Enzon shall not be required to pay the amount required under Section 7.3 more than once in any [**Redacted**] period pursuant to the terms of Section 7.3. Following Enzon’s [**Redacted**], which shall last no longer than [**Redacted**], Santaris shall at Santaris’ cost provide Enzon with one and [**Redacted**] of substance for [**Redacted**] LNA Compounds (identified by Enzon) meeting the applicable Compound Acceptance Criteria for an Additional Target (each of which is an Accepted LNA Compound). Enzon shall have the right to synthesize or have synthesized by a Third Party, at Enzon’s sole cost, additional quantities of any and all LNA Compounds delivered by Santaris, as well as quantities of any additional LNA Compounds disclosed in the written reports provided by Santaris pursuant to this Section 5.4 that also meet the applicable Compound Acceptance Criteria (each such additional LNA Compound synthesized by or for Enzon, if any shall also be an Accepted LNA Compound).
Compound Selection. The Research Committee will decide which libraries of ArQule Compounds to screen in the Collaboration (e.g., Compass Array Sets, Biased Array Sets, or Mapping Array Sets, as described in the Collaboration Plan). The Research Committee may also decide to screen Targeted Compounds in focused libraries developed by the parties for a target class, if any, as described in the Collaboration Plan. The Research Committee may also decide to screen Analog Compounds developed by the parties for a different ACADIA Target.
Compound Selection. Each LNA Compound delivered by Santaris to Enzon will be identified by Santaris pursuant to the selection process set forth in Schedule 5.4A (the “Compound Selection Process”), and shall satisfy the acceptance criteria set forth for such Additional Target in Schedule 5.4B (the “Compound Acceptance Criteria”). Following the Compound Selection Process, Santaris shall provide Enzon with a written report detailing the results of such process, including its design, synthesis and screening efforts, as well as the sequences of any and all LNA Compounds resulting from such process that meet the Compound Acceptance Criteria. Upon delivery by Santaris of at least [**Redacted**] of substance for at least two (2) LNA Compounds meeting the applicable Compound Acceptance Criteria for an Additional Target (each of which is an “Accepted LNA Compound”), Enzon shall pay the amount required under Section 7.3. Enzon shall have the right to synthesize or have synthesized by a Third Party, at Enzon’s sole cost, additional quantities of any and all LNA Compounds delivered by Santaris, as well as quantities of any additional LNA Compounds disclosed in the written report provided by Santaris pursuant to this Section 5.4 that also meets the applicable Compound Acceptance Criteria (each such additional LNA compound synthesized by or for Enzon, if any shall also be an Accepted LNA Compound).
Compound Selection. The Parties shall use reasonable good faith efforts to, within ninety (90) Calendar Days of the Effective Date (such period, the “Selection Period”), agree in writing on the API to be incorporated into the third Initial LiquiTime Product (other than those incorporating [***] and [***]) to be developed pursuant to Section 4.2 and with respect to which API and corresponding Products rights are granted under Section 2.1, provided that, in the event the Parties do not agree on such API within the Selection Period, Cerecor shall be entitled, upon written notice to Avadel given at any time within fifteen (15) Calendar Days of the end of the Selection Period, to select stiripentol or any other API as the “Selected Compound” for purposes of this Agreement.
Compound Selection. MERCK shall nominate MERCK compounds during the Research Program for which Information Rich Clinical Trials shall be conducted by the Parties according to the Work Plan. deCODE shall be given the opportunity to review each proposed compound to confirm that deCODE’s conduct of one or more IRCTs on such compound under this Agreement would not conflict with any other ongoing deCODE project(s). The Operating Committee shall select which MERCK nominated compounds will become Selected Compounds; PROVIDED, HOWEVER, that solely with respect to compounds in the Non-exclusive Disease Area, deCODE shall not be obligated to perform development efforts with respect to any such compounds if it reasonably believes that the performance of such efforts will conflict with any ongoing deCODE project(s).
Compound Selection. A compound meeting the [***] will be considered as a Recommended Compound. Designation of the Recommended Compound will be [***].
Compound Selection. The Company will select at least 1,300 Company Library Compounds which fully represent the mechanistic and structural diversity of approved compounds. Upon the request of the Foundation, the Company Library Compounds can be prioritized by their likelihood of crossing the BBB, based on the Company's internal BBB ranking. The Company's internal analysis takes the factors into consideration: (a) known CNS effect in humans, as demonstrated by therapeutic class or documented side-effect in the literature, (b) the ability to cross BBB in experimental system, as demonstrated by published experiments and (c) in silico prediction of BBB partitioning, based on chemical structure. The up to 300 Foundation Selected Compounds to be screened will be selected from the following categories: 50-100 compounds from the Foundation's secondary screening consortium, 208 compounds that the Foundation has identified from the literature as potentially being of interest for Huntington disease, and approximately 100 biological agents that have been reported to be of interest to Huntington disease. These lists will be cross referenced with the Company collection to identify compounds that are already available at the Company, and up to 300 of those that are not will be acquired by the Company. The precise number of Foundation Selected Compounds acquired will depend on their availability. The Company will discuss the possibility of formatting the biological agents for screening with EMD Biosciences. If the Company does not reach an acceptable arrangement with this or another supplier, the Company will purchase these proteins individually, then format them in 384-well plates, heeding the manufacturers' instructions regarding storage conditions.
Compound Selection. The Steering Committee (described below) will jointly select and prioritize those compounds from the NCI repository for use in conjunction with the Protarga technology, and determine which Targaceutical-TM- Carrier or Carriers might be most appropriate. Compound selection will be based on at least the following criteria: novel mechanism of compound action, need to reduce toxicity or increase efficacy of the compound based on prior data, appropriate chemical group on the compound for conjugating to a chosen carrier, availability of sufficient compound in the NCI library, and whether the compound is synthetic or natural. The NCI and Protarga will decide on an appropriate plan for initial IN VITRO and IN VIVO testing of the Targaceutical-TM- Conjugates. STEERING COMMITTEE A joint steering committee will be established, with equal participation by NCI and Protarga (Steering Committee). The Steering Committee shall be comprised of the Principal Investigators on the CRADA plus appropriate staff, as needed. These Investigators will be authorized by NCI and Protarga, respectively, to determine such things as, but not limited to, which Targaceutical-TM- Conjugates are synthesized and tested under the CRADA and which testing protocols will be used. The Investigators would be encouraged to elicit expert recommendations from their respective organizations prior to each Steering Committee meeting. The Steering Committee will determine the frequency and location of its meetings. NCI and Protarga contemplate that the scope and type of synthesis and testing will evolve commensurate with scientific progress, and the Committee will be encouraged to harness the resources of both organizations.
Compound Selection
